Topline Outcomes from Portion 2 CELIA Peek of Diranersen (BIIB080): First Peek to Uncover Reduction in Tau Pathology and Cognitive Profit in Sufferers with Early Alzheimer’s Illness – Biogen
Breakthrough in Alzheimer’s research: Topline Results from the Phase 2 CELIA Study of Diranersen (BIIB080) The landscape of Alzheimer’s disease […]


